Sign Out
Caution should be considered in patients with intravascular volume depletion, conditions with stimulation of the renin-angiotensin-aldosterone system, renovascular hypertension, renal impairment and kidney transplantation, hyperkalemia, aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy, primary aldosteronism, hepatic impairment, and patients on lithium therapy.
As with any antihypertensive agent, excessive decrease in blood pressure in patients with ischemic heart disease or ischemic cerebrovascular disease could result in a myocardial infarction or stroke.
Use in Lactation: Mothers must not breastfeed during olmesartan medoxomil therapy.
Continue with Google